Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX001899 in KRAS G12C-mutant advanced solid tumors and non-small cell lung cancer
ChiCTR2200059986Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sosimerasib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Incidence of dose-limiting toxicity, Maximum tolerated dose and 2 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
sosimerasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200059986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059986.